Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 41, Issue 3, 1998, Pages 511-517

  Ennis, Ronald D ^a   Malyszko, Bozena K ^a   Heitjan, Daniel F ^b   Rubin, Mark A ^a   O'Toole, Kathleen M ^a   Schiff, Peter B ^a  

^a Coll Phys Surgs Columbia Univ ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

ASTRO consensus conference; Biochemical disease free survival; Prostate; Prostate cancer; Prostate specific antigen; PSA; Radiation therapy; Radiotherapy

Indexed keywords

BIOCHEMICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE; TREATMENT FAILURE;

CONSENSUS DEVELOPMENT CONFERENCES; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, COMPUTER-ASSISTED; TREATMENT FAILURE;

EID: 0031748460     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00104-7     Document Type: Article

References (26)

1. Rosenzweig K.E., Morgan W.R., Lytton B., Peschel R.E. Prostate specific antigen following radiotherapy for local prostate cancer. J. Urol. 153:1995;1561-1564.
2. Stein A., deKernion J.B., Smith R.B., Dorey F., Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J. Urol. 147:1992;942-946.
3. Lange P.H., Ercole C.J., Lightner D.J., Fraley E.E., Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141:1989;873-879.
4. Lee W.R., Hanks G.E., Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer Clinical observations . J. Clin. Oncol. 15:1997;230-238.
5. Zagars G.K., von Eschenbach A.C. Prostate-specific antigen An important marker for prostate cancer treated by external beam radiation therapy . Cancer. 72:1993;538-548.
6. Oesterling J.E., Chan D.W., Epstein J.I., Kimball A.W., Bruzek D.J., Rock R.C., et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139:1988;766-772.
7. Meek A.G., Park T.L., Oberman E., Wielopolski L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 19:1990;733-741.
8. Vijayakumar S., Quadri S.F., Karrison T.G., Trinidad C.O., Chan S-K, Halpern H.J., et al. Localized prostate cancer Use of serial prostate-specific antigen measurements during radiation therapy . Radiology. 184:1992;271-274.
9. Cox R.S., Kaplan I.D., Bagshaw M.A. Prostate-specific antigen kinetics after external beam irradiation for carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 28:1993;23-31.
10. Ritter M.A., Messing E.M., Shanahan T.G., Potts S., Chappell R.J., Kinsella T.J. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10:1992;1208-1217.
11. Zietman A.L., Coen J.J., Shipley W.U., Willett C.G., Efird J.T. Radical radiation therapy in the management of prostatic adenocarcinoma The initial prostate specific antigen value as a predictor of treatment outcome . J. Urol. 151:1994;640-645.
12. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostate carcinoma. J. Clin. Oncol. 14:1996;449-453.
13. Kavadi V.S., Zagars G.K., Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer Prognostic implications . Int. J. Radiat. Oncol. Biol. Phys. 30:1994;279-287.
14. Critz F.A., Levinson A.K., Williams W.H., Holladay D.A. Prostate-specific antigen nadir The optimum level after irradiation for prostate cancer . J. Clin. Oncol. 14:1996;2893-2900.
15. Willett C.G., Zietman A.L., Shipley W.U., Coen J.J. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J. Urol. 151:1994;1579-1581.
16. Ennis R.D., Malyszko B.K., Rescigno J., Whitman A.E., Heitjan D.F., O'Toole K.M., et al. Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer A proposal based on patients treated with external beam radiotherapy . Urology. 51:1998;265-270.
17. Ingenito A.C., Ennis R.D., Hsu I-C, Begg M.D., Benson M.C., Schiff P.B. Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer. Urology. 50:1997;73-78.
18. Lee W.R., Hanks G.E., Schultheiss T.E., Corn B.W., Hunt M.A. Localized prostate cancer treated by external beam radiotherapy alone Serum prostate specific antigen driven outcome analysis . J. Clin. Oncol. 13:1995;464-469.
19. Zagars G.K., Pollack A., vonEschenbach A.C. Prognostic factors for clinically localized prostate carcinoma. Cancer. 79:1997;1370-1380.
20. Pisansky T.M., Kahn M.J., Rasp G.M., Cha S.S., Haddock M.G., Bostwick D.G. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 79:1997;337-344.
21. Horowitz E.M., Vicini F.A., Ziaja E.L., Gonzalez J., Dmuchowski C.F., Stromberg J.S., et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int. J. Radiat. Oncol. Biol. Phys. 36:1996;565-571.
22. Consensus statement Guidelines for PSA following radiation therapy . Int. J. Radiat. Oncol. Biol. Phys. 37:1997;1035-1041.
23. Oesterling J.E., Movad M.A., Wright G.L., Beck G.R. An analytical comparison of the three most commonly used prostate-specific antigen assays Tandem-R, Tandem-E and IMx . Urology. 46:1995;524-532.
24. Oesterling J.E., Martin S.K., Bergstralh E.J., Lowe F.C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA. 269:1993;57-60.
25. Beahrs O.H., Henson D.E., Hutter R.V.P., Kennedy B.J. Manual for staging of cancer. 4th ed. 1992;181-186 J. B. Lipincott, Philadelphia, PA.
26. Zentner P.G., Pao L.K., Benson M.C., McMahon D.J., Schiff P.B. Prostate-specific antigen density A new prognostic indicator for prostate cancer . Int. J. Radiat. Oncol. Biol. Phys. 27:1993;47-58.